Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology

Affiliations

¹ Tufts University School of Medicine, Boston, MA, USA.
² Penn State Hershey Medical Center, Hershey, PA, USA.
³ EMD Serono Inc., Rockland, MA, USA.
⁴ Director, GI Cancers and Leader of Experimental Therapeutics, Tufts University School of Medicine, 800 Washington Street, Boston, MA 02111, USA.

Matthew J Abrams et al. Therap Adv Gastroenterol. 2016 Mar.

. 2016 Mar;9(2):141-51.

doi: 10.1177/1756283X15622601.

¹ Tufts University School of Medicine, Boston, MA, USA.
² Penn State Hershey Medical Center, Hershey, PA, USA.
³ EMD Serono Inc., Rockland, MA, USA.
⁴ Director, GI Cancers and Leader of Experimental Therapeutics, Tufts University School of Medicine, 800 Washington Street, Boston, MA 02111, USA.

No abstract available

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

1. American Cancer Society (2015) Cancer Facts and Figures.
1. Barbour A., O’Rourke N., Chandrasegaram M. (2015) A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: the AGITG GAP Study. J Clin Oncol 33: 4115.
1. Berger A., Garcia M., Jr, Hoffman J., Regine W., Abrams R., Safran H., et al. (2008) Postresection CA19-9 predicts OS in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26: 5918–5922. - PMC - PubMed
1. Breslin T., Hess K., Harbison D., Jean M., Cleary K., Dackiw A., et al. (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8: 123–132. - PubMed
1. Calegari M., Orlandi A., Indellicati G., Martini M., Cocomazzi A., Bagalà C., et al. (2015) Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma. J Clin Oncol 33: E15295. - PubMed